NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2
CONCLUSIONS: This study provides new molecular insights into the role of NANOG as a key determinant of pluripotency in TGCTs through the regulation of MIR9-2-5p, a novel epigenetic modulator of cancer stemness. Our data also highlight the potential negative feedback mediated by MIR9-2-5p on NANOG expression, which could be exploited as a therapeutic strategy for the treatment of TGCTs.PMID:38693576 | DOI:10.1186/s13287-024-03724-1 (Source: Cell Research)
Source: Cell Research - May 1, 2024 Category: Cytology Authors: Ryan P Cardenas Ahmad Zyoud Alan McIntyre Ramiro Alberio Nigel P Mongan Cinzia Allegrucci Source Type: research
NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2
CONCLUSIONS: This study provides new molecular insights into the role of NANOG as a key determinant of pluripotency in TGCTs through the regulation of MIR9-2-5p, a novel epigenetic modulator of cancer stemness. Our data also highlight the potential negative feedback mediated by MIR9-2-5p on NANOG expression, which could be exploited as a therapeutic strategy for the treatment of TGCTs.PMID:38693576 | DOI:10.1186/s13287-024-03724-1 (Source: Cancer Control)
Source: Cancer Control - May 1, 2024 Category: Cancer & Oncology Authors: Ryan P Cardenas Ahmad Zyoud Alan McIntyre Ramiro Alberio Nigel P Mongan Cinzia Allegrucci Source Type: research
Testicular Cancer Treatments and Sexuality: A Narrative Review
Medicina (Kaunas). 2024 Mar 31;60(4):586. doi: 10.3390/medicina60040586.ABSTRACTThe incidence of testicular cancer (TC) has been rapidly increasing over the past years. Diagnosis and early treatment have shown good oncological control, guaranteeing the patient different treatment approaches according to histology and tumor stage. Currently, physicians usually prioritize oncological outcomes over sexual outcomes and quality of life, considering as a first aim the overall survival of the patients; however, differently from other neoplasms, quality of life is still strongly affected among TC patients, and sexual outcomes are ...
Source: Cancer Control - April 27, 2024 Category: Cancer & Oncology Authors: Massimiliano Raffo Angelo Di Naro Luigi Napolitano Achille Aveta Simone Cilio Savio Domenico Pandolfo Celeste Manfredi Chiara Lonati Nazareno Roberto Suardi Source Type: research
Fertility preservation in males with cancer of trends, region development, and efficacy in mainland China from 16 regions Chinese sperm banks
ConclusionThis study provides the first comprehensive national statistical census and review of fertility preservation in male cancer patients with respect to trends, prevalence, and cancer types. The development of male cancer fertility preservation in China is imbalanced and percentage of males receiving sperm cryopreservation in the adolescent and young adult cancers was low. Sixteen human sperm banks from China analyze current problems and challenges, and then prioritize steps toward the achievement of the FP strategy framework for Healthy China 2030. (Source: Journal of Assisted Reproduction and Genetics)
Source: Journal of Assisted Reproduction and Genetics - April 27, 2024 Category: Reproduction Medicine Source Type: research
Evaluation and Management of Testicular Cancer After Late Relapse
Oncology (Williston Park). 2024 Apr 11;38(4):142-146. doi: 10.46883/2024.25921018.ABSTRACTA 41-year-old man presented to his primary care physician with a 1-month history of left neck adenopathy in the context of a history of nonseminomatous germ cell tumors (NSGCTs). In 2011, the patient was treated for stage IB (T2N0M0S0) right-sided NSGCTs of the testis, which were 95% embryonal and 5% yolk sac tumors. He underwent a right radical orchiectomy and was followed until 2022 without recurrence. In the work-up for his adenopathy, laboratory results for human chorionic gonadotropin, lactate dehydrogenase, and α-fetoprotein we...
Source: Oncology (Williston Park, N.Y.) - April 25, 2024 Category: Cancer & Oncology Authors: Joanna L Langner Frederick Millard Vera Vavinskaya Haiyan Zhang Nuphat Yodkhunnatham Aditya Bagrodia Source Type: research
Evaluation and Management of Testicular Cancer After Late Relapse
Oncology (Williston Park). 2024 Apr 11;38(4):142-146. doi: 10.46883/2024.25921018.ABSTRACTA 41-year-old man presented to his primary care physician with a 1-month history of left neck adenopathy in the context of a history of nonseminomatous germ cell tumors (NSGCTs). In 2011, the patient was treated for stage IB (T2N0M0S0) right-sided NSGCTs of the testis, which were 95% embryonal and 5% yolk sac tumors. He underwent a right radical orchiectomy and was followed until 2022 without recurrence. In the work-up for his adenopathy, laboratory results for human chorionic gonadotropin, lactate dehydrogenase, and α-fetoprotein we...
Source: Oncology (Williston Park, N.Y.) - April 25, 2024 Category: Cancer & Oncology Authors: Joanna L Langner Frederick Millard Vera Vavinskaya Haiyan Zhang Nuphat Yodkhunnatham Aditya Bagrodia Source Type: research
Evaluation and Management of Testicular Cancer After Late Relapse
Oncology (Williston Park). 2024 Apr 11;38(4):142-146. doi: 10.46883/2024.25921018.ABSTRACTA 41-year-old man presented to his primary care physician with a 1-month history of left neck adenopathy in the context of a history of nonseminomatous germ cell tumors (NSGCTs). In 2011, the patient was treated for stage IB (T2N0M0S0) right-sided NSGCTs of the testis, which were 95% embryonal and 5% yolk sac tumors. He underwent a right radical orchiectomy and was followed until 2022 without recurrence. In the work-up for his adenopathy, laboratory results for human chorionic gonadotropin, lactate dehydrogenase, and α-fetoprotein we...
Source: Oncology (Williston Park, N.Y.) - April 25, 2024 Category: Cancer & Oncology Authors: Joanna L Langner Frederick Millard Vera Vavinskaya Haiyan Zhang Nuphat Yodkhunnatham Aditya Bagrodia Source Type: research
Evaluation and Management of Testicular Cancer After Late Relapse
Oncology (Williston Park). 2024 Apr 11;38(4):142-146. doi: 10.46883/2024.25921018.ABSTRACTA 41-year-old man presented to his primary care physician with a 1-month history of left neck adenopathy in the context of a history of nonseminomatous germ cell tumors (NSGCTs). In 2011, the patient was treated for stage IB (T2N0M0S0) right-sided NSGCTs of the testis, which were 95% embryonal and 5% yolk sac tumors. He underwent a right radical orchiectomy and was followed until 2022 without recurrence. In the work-up for his adenopathy, laboratory results for human chorionic gonadotropin, lactate dehydrogenase, and α-fetoprotein we...
Source: Oncology (Williston Park, N.Y.) - April 25, 2024 Category: Cancer & Oncology Authors: Joanna L Langner Frederick Millard Vera Vavinskaya Haiyan Zhang Nuphat Yodkhunnatham Aditya Bagrodia Source Type: research
Evaluation and Management of Testicular Cancer After Late Relapse
Oncology (Williston Park). 2024 Apr 11;38(4):142-146. doi: 10.46883/2024.25921018.ABSTRACTA 41-year-old man presented to his primary care physician with a 1-month history of left neck adenopathy in the context of a history of nonseminomatous germ cell tumors (NSGCTs). In 2011, the patient was treated for stage IB (T2N0M0S0) right-sided NSGCTs of the testis, which were 95% embryonal and 5% yolk sac tumors. He underwent a right radical orchiectomy and was followed until 2022 without recurrence. In the work-up for his adenopathy, laboratory results for human chorionic gonadotropin, lactate dehydrogenase, and α-fetoprotein we...
Source: Oncology (Williston Park, N.Y.) - April 25, 2024 Category: Cancer & Oncology Authors: Joanna L Langner Frederick Millard Vera Vavinskaya Haiyan Zhang Nuphat Yodkhunnatham Aditya Bagrodia Source Type: research
Evaluation and Management of Testicular Cancer After Late Relapse
Oncology (Williston Park). 2024 Apr 11;38(4):142-146. doi: 10.46883/2024.25921018.ABSTRACTA 41-year-old man presented to his primary care physician with a 1-month history of left neck adenopathy in the context of a history of nonseminomatous germ cell tumors (NSGCTs). In 2011, the patient was treated for stage IB (T2N0M0S0) right-sided NSGCTs of the testis, which were 95% embryonal and 5% yolk sac tumors. He underwent a right radical orchiectomy and was followed until 2022 without recurrence. In the work-up for his adenopathy, laboratory results for human chorionic gonadotropin, lactate dehydrogenase, and α-fetoprotein we...
Source: Oncology (Williston Park, N.Y.) - April 25, 2024 Category: Cancer & Oncology Authors: Joanna L Langner Frederick Millard Vera Vavinskaya Haiyan Zhang Nuphat Yodkhunnatham Aditya Bagrodia Source Type: research
Evaluation and Management of Testicular Cancer After Late Relapse
Oncology (Williston Park). 2024 Apr 11;38(4):142-146. doi: 10.46883/2024.25921018.ABSTRACTA 41-year-old man presented to his primary care physician with a 1-month history of left neck adenopathy in the context of a history of nonseminomatous germ cell tumors (NSGCTs). In 2011, the patient was treated for stage IB (T2N0M0S0) right-sided NSGCTs of the testis, which were 95% embryonal and 5% yolk sac tumors. He underwent a right radical orchiectomy and was followed until 2022 without recurrence. In the work-up for his adenopathy, laboratory results for human chorionic gonadotropin, lactate dehydrogenase, and α-fetoprotein we...
Source: Oncology (Williston Park, N.Y.) - April 25, 2024 Category: Cancer & Oncology Authors: Joanna L Langner Frederick Millard Vera Vavinskaya Haiyan Zhang Nuphat Yodkhunnatham Aditya Bagrodia Source Type: research
Evaluation and Management of Testicular Cancer After Late Relapse
Oncology (Williston Park). 2024 Apr 11;38(4):142-146. doi: 10.46883/2024.25921018.ABSTRACTA 41-year-old man presented to his primary care physician with a 1-month history of left neck adenopathy in the context of a history of nonseminomatous germ cell tumors (NSGCTs). In 2011, the patient was treated for stage IB (T2N0M0S0) right-sided NSGCTs of the testis, which were 95% embryonal and 5% yolk sac tumors. He underwent a right radical orchiectomy and was followed until 2022 without recurrence. In the work-up for his adenopathy, laboratory results for human chorionic gonadotropin, lactate dehydrogenase, and α-fetoprotein we...
Source: Oncology (Williston Park, N.Y.) - April 25, 2024 Category: Cancer & Oncology Authors: Joanna L Langner Frederick Millard Vera Vavinskaya Haiyan Zhang Nuphat Yodkhunnatham Aditya Bagrodia Source Type: research
Long-term quality of life of testicular cancer survivors differs according to applied adjuvant treatment and tumour type
ConclusionsThe applied adjuvant treatment and the tumour entity had a significant impact on the long-term QoL of TC survivors, even more than 25 years after the completion of therapy. Both RT and CT had a negative impact compared to survivors treated with RPLND, except for sexual concerns. NSGCT survivors had a lower impairment of QoL compared to seminoma survivors, except in terms of sexual concerns.Implications for Cancer SurvivorsImplications for cancer survivors are to raise awareness of aspects of long-term and late effects on QoL in TC survivors; offer supportive care, such as psycho-oncological support or lifestyl...
Source: Journal of Cancer Survivorship - April 24, 2024 Category: Cancer & Oncology Source Type: research
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
AbstractPurpose of ReviewOur review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody –drug conjugate (ADC) development, emphasising their transformative potential in cancer care.Recent FindingsADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA ’s approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ...
Source: Current Oncology Reports - April 23, 2024 Category: Cancer & Oncology Source Type: research
